Solomon Langermann
Assistant Professor AdjunctCards
About
Research
Publications
2024
632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC)
Barbu A, Kothari P, Kahan S, Christenson E, Kazmi S, Manda S, Chisamore M, Kordahi S, Martz A, Nelson M, Morawski A, Flies D, Langermann S, Guha U, Myint H. 632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC). 2024, a727-a727. DOI: 10.1136/jitc-2024-sitc2024.0632.Peer-Reviewed Original Research577P Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
Christenson E, Kazmi S, Mahadevan D, Sohal D, Manda S, Martz A, Kordahi S, Zika M, Kothari P, Kahan S, Barbu E, Morawski A, Flies D, Langermann S, Chisamore M, Fu S, Wadlow R, Guha U, Myint H, Le D. 577P Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients. Annals Of Oncology 2024, 35: s468. DOI: 10.1016/j.annonc.2024.08.646.Peer-Reviewed Original Research758P Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients
Zsiros E, Christenson E, Sohal D, Manda S, Fu S, Martz A, Zika M, Kordahi S, Kothari P, Kahan S, Barbu E, Morawski A, Flies D, Langermann S, Chisamore M, Guha U, Myint H, Mahadevan D. 758P Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients. Annals Of Oncology 2024, 35: s575. DOI: 10.1016/j.annonc.2024.08.819.Peer-Reviewed Original ResearchBCAM (basal cell adhesion molecule) protein expression in different tumor populations
Burela S, He M, Trontzas I, Gavrielatou N, Schalper K, Langermann S, Flies D, Rimm D, Aung T. BCAM (basal cell adhesion molecule) protein expression in different tumor populations. Discover Oncology 2024, 15: 381. PMID: 39207605, PMCID: PMC11362396, DOI: 10.1007/s12672-024-01244-1.Peer-Reviewed Original ResearchPD-L1 expressionBasal cell adhesion moleculePD-L1Quantitative immunofluorescenceAssociated with better OSPD-L1 protein expressionCancer typesBladder urothelial tumorsProtein expressionMultiple immune checkpointsHead and neckMultiple tumor typesEvidence of hypermethylationImmune checkpointsImmunotherapy responseCell adhesion moleculesTumor typesValidation cohortTumor populationCancer patientsTumorPredictive valueAdhesion moleculesNovel biomarkersWidespread expressionA phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
Christenson E, Mahadevan D, Kazmi S, Manda S, Sohal D, Hutson T, Fu S, Martz A, Kordahi S, Barbu E, Flies D, Langermann S, Chisamore M, Gutierrez M, Matrana M, Spira A, Wadlow R, Guha U, Myint H, Le D. A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. Journal Of Clinical Oncology 2024, 42: 2538-2538. DOI: 10.1200/jco.2024.42.16_suppl.2538.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune cell infiltrationOvarian cancerColorectal cancerICI therapyCell infiltrationAdvanced metastatic colorectal cancerPromote immune cell infiltrationResistance to ICI therapyEffector memory T cellsPeripheral blood immunophenotypingPhase 1b/2 studyDose of pembrolizumabData cut-offMetastatic colorectal cancerMetastatic solid tumorsMemory T cellsColorectal cancer subjectsImmune cell functionHuman IgG1 Fc domainAnti-tumor activityTumor extracellular matrixModified toxicity probability intervalExtracellular matrixCheckpoint inhibitorsThe FLRT3-UNC5B Pathway is a Novel Regulator of T Immunosurveillance
Flies D, Yan C, Yang Q, Arbitman S, Fitzgerald D, Sharee S, Shaik J, Bosiacki J, Myers K, Paucarmayta A, Johnson D, O'Neill T, Cusumano Z, Langermann S, Langenau D, Patel S. The FLRT3-UNC5B Pathway is a Novel Regulator of T Immunosurveillance. The Journal Of Immunology 2024, 212: 0298_5492-0298_5492. DOI: 10.4049/jimmunol.212.supp.0298.5492.Peer-Reviewed Original ResearchT cell activationT cellsCell-derived xenograftsTumor growthT cell anti-tumor immunityInhibitor of T cell activationCell-derived xenograft modelControl T cell responsesHuman T cell functionT cell checkpointsAnti-tumor immunityT cell responsesT cell functionActivated T cellsTumor-immune interactionsPromote tumor growthHuman T cellsCAR-TUNC-5 netrin receptor BZebrafish tumor modelTumor cellsTumor modelReceptor BGain-of-function screenMonoclonal antibodiesTumor expressed BCAM impedes anti-tumor T cell immunity and can be targeted therapeutically
Flies D, Tian L, O'Neill R, Fitzgerald D, Sharee S, Shaik J, Bosiacki J, Paucarmayta A, Prajapati K, Langermann S, Mrass P. Tumor expressed BCAM impedes anti-tumor T cell immunity and can be targeted therapeutically. The Journal Of Immunology 2024, 212: 0517_5466-0517_5466. DOI: 10.4049/jimmunol.212.supp.0517.5466.Peer-Reviewed Original ResearchAnti-tumor immunityT cell immunityCytotoxic T cellsTumor microenvironmentT cellsTumor growthAnti-tumor T cell immunityT cell anti-tumor immunityExclusion of T cellsIncreased T-cell infiltrationRegulating T cell immunityHuman T cell functionT cell infiltrationInhibitor of T cell proliferationT cell suppressionHuman tumors in vitroT cell functionReduced tumor growthT cell proliferationDecreased tumor growthTumors in vitroTumor growth in vivoCancer escapeCheckpoint inhibitorsGrowth in vivoUp-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
Zhang T, Yu W, Cheng X, Yeung J, Ahumada V, Norris P, Pearson M, Yang X, van Deursen W, Halcovich C, Nassar A, Vesely M, Zhang Y, Zhang J, Ji L, Flies D, Liu L, Langermann S, LaRochelle W, Humphrey R, Zhao D, Zhang Q, Zhang J, Gu R, Schalper K, Sanmamed M, Chen L. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity. Science Immunology 2024, 9: eadh2334. PMID: 38669316, DOI: 10.1126/sciimmunol.adh2334.Peer-Reviewed Original ResearchConceptsT cell infiltrationT cell exclusionT cellsResistance to anti-PD-1 immunotherapyPoor T-cell infiltrationAnti-PD-1 immunotherapyImmunogenic mouse tumorsT cell mobilizationHuman cancer tissuesTherapeutic immunotherapyCancer immunotherapyMouse tumorsChemokine systemImmunotherapyTumor tissuesImpaired infiltrationTumorLipid metabolitesHuman cancersCancer tissuesInfiltrationA2 groupCancerPLA2G10Up-regulatedThe FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies
Prajapati K, Yan C, Yang Q, Arbitman S, Fitzgerald D, Sharee S, Shaik J, Bosiacki J, Myers K, Paucarmayta A, Johnson D, O’Neill T, Kundu S, Cusumano Z, Langermann S, Langenau D, Patel S, Flies D. The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies. Science Advances 2024, 10: eadj4698. PMID: 38427724, PMCID: PMC10906930, DOI: 10.1126/sciadv.adj4698.Peer-Reviewed Original ResearchConceptsFibronectin leucine-rich transmembrane protein 3T cellsHuman T cellsCancer immunotherapyT cell-based cancer immunotherapyInhibit T cell activationT cell checkpointsActivated human T cellsT cell immunityT cell killingT cell activationHuman cancer modelsImmune-dependent mannerAxon guidance proteinsTarget such mechanismsCAR-TCoinhibitory receptorsGuidance proteinsTumor immunityClinical benefitCancer modelsTumor growthCancer cellsHuman cancersMonoclonal antibodiesLeukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice
Singh A, Mommers-Elshof E, Vijver S, Jansen J, Gonder S, Lebbink R, Bihan D, Farndale R, Boon L, Langermann S, Leusen J, Flies D, Meyaard L, Pascoal Ramos M. Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice. Cancer Immunology, Immunotherapy 2024, 73: 16. PMID: 38236251, PMCID: PMC10796629, DOI: 10.1007/s00262-023-03600-6.Peer-Reviewed Original ResearchConceptsLeukocyte-associated immunoglobulin-like receptor-1Increase tumor controlTumor controlAnti-programmed death-ligand 1Mouse modelT cells in vitroMouse T cells in vitroIncreased tumor clearanceAnti-tumor responsesDeath-ligand 1Immunocompetent mouse modelReduced tumor burdenControl tumor growthHumanized mouse modelIn vivo tumor modelsWild type miceAssociated with tumor developmentPD-L1Tumor burdenTumor clearanceConventional immunotherapyImmunocompetent miceTumor outgrowthTherapy responseTumor microenvironment